ArticleEuropean journal of rheumatology2025
Hearing Loss in Connective Tissue Diseases: A Systematic Review.
Article in European journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hearing loss may be found in patients with systemic autoimmune disorders such as connective tissue diseases (CTD). This work aimed to review the literature on ear involvement in CTD. A systematic search of articles published in PubMed/MEDLINE, EMBASE, and SCOPUS from 1966 to June 2023 following PRISM guidelines was done. Seventy-nine papers were selected: 39 on rheumatoid arthritis; 16 on systemic lupus erythematosus; 14 on scleroderma; 6 on Sjogren's syndrome; 1 on mixed connective tissue disease; and 3 that approached more than one CTD. Most of them showed that hearing loss (HL) in connective tissue disease patients was higher than in controls, mainly of the sensorineural type and at high frequencies. Associations with clinical features and autoantibodies profile of underlying conditions varied widely among the results. In conclusion, sensorineural hearing loss is common in individuals with CTD, and it is essential to be aware of this complication in order to establish an effective treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.